|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1009 Duke Street |
Address2 |
|
City | Alexandria |
State | VA |
Zip Code | 22314 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 8101-315
|
||||||||
|
6. House ID# 308130024
|
TYPE OF REPORT | 8. Year | 2018 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: William A. Finerfrock, President |
Date | 1/17/2019 3:33:07 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Funding for asthma and allergy programs, health care quality, pediatric graduate medical education and health information technology initiatives and Medicaid/Medicare in the appropriations bill for the Department of Health and Human Services for FY 2017.
Medicare payment cuts affecting physicians due to Sequestration.
FDA appropriations as included in the Agriculture Appropriations bill for FY 2019.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William A. |
Finerfrock |
|
|
|
Matt |
Reiter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Legislation to fix or affecting the Medicare Physician Fee problem and Graduate Medical Education.
Support to repeal IPAB.
Patients over paper work initiative
Regulations implementing Affordable Care Act, HIT, ACO's, Physician Fee Schedule, Medicare fraud and abuse, electronic records for ICD-10.
Possible reforms to Medicare Graduate Medical Education funding.
Regulations implementing the Medicare Access and CHIP Reauthorization Act of 2015.
Regulations proposing changes to the Part B Drug Payment Model (CMS-1670-P).
Support for Medicare Telehealth Parity
Medicare Physician Fee Schedule issues
Support for continuation of Medicare Demonstration project for Medicare IVIG Therapy Access
support for reauthorization of the CHIP program
Possible changes to the 340B Prescription drug program
Issues related to development of alternative payment models
Proposed changes to E/M coding documentation and Medicare payments
Development and approval of Alternative Payment Models by CMMI using Physician Focused Payment Model process
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William A. |
Finerfrock |
|
|
|
Matt |
Reiter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
FDA Conflict of Interest issue, Compounding issue and implementation of FDA regulations and FDA issues affecting Allergists and their patients.
Monitor and track: Health Information Technology issues; Asthma & Allergy Legislation, Clinical Research, healthcare quality, patient safety initiatives and health care reform.
Support Health Care Truth & Transparency Act.
Support authorization of Children Hospital Graduate Medical Education program.
Issues of network adequacy in Qualified Health Plans and its impact on patients with chronic diseases.
ACA implementation in general and its impact on workforce and supply.
Development of Alternative payment Models and development of bundled payments for asthma care.
Support School-Based Asthma Management Program Act.
Regulations restricting smoking in Federal housing complex.
Encourage Members of Congress to join the Allergy Caucus
Support legislation Federal designed to address step-therapy issues
Support for continuation of Medicare Demonstration of IVIG Therapy
Proposed FDA Guidance document for compounding/mixing of allergy extracts
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Natl Economic Council (NEC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William A. |
Finerfrock |
|
|
|
Matt |
Reiter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |